ValiRx (ValiRx PLC (AIM:VAL)), Suzanne Dilly (CEO) Cenkos Securities Growth & Innovation Forum on Tuesday 8th February 2022
ValiRx PLC (AIM:VAL) is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering. We focus on the novel treatments of cancers and associated Biomarkers. Our technologies and products however can also be applied to the other fields as well, such as neurology and inflammatory diseases. The company listed on the Alternative Investment Market (“AIM”) of the London Stock Exchange in October 2006 and is focused on creating a portfolio of innovative products through investment in specific development projects. We actively manage projects within this portfolio.